NCT03663478

Brief Summary

The aim of this study is to investigate whether it is possible to prolong time to first opioid with the TQL block by inserting catheters bilaterally, providing continuous analgesia, in patients undergoing elective CS. Our hypothesis is that it will be possible to significantly extend time to first opioid with the blockade by 66.6%, increasing it from a mean of 5.6 hours to a mean of 10 hours.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
32

participants targeted

Target at below P25 for phase_4 postoperative-pain

Timeline
Completed

Started Sep 2018

Typical duration for phase_4 postoperative-pain

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 4, 2018

Completed
Same day until next milestone

Study Start

First participant enrolled

September 4, 2018

Completed
6 days until next milestone

First Posted

Study publicly available on registry

September 10, 2018

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 8, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 8, 2020

Completed
Last Updated

March 3, 2021

Status Verified

March 1, 2021

Enrollment Period

1.6 years

First QC Date

September 4, 2018

Last Update Submit

March 2, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Time to first opioid

    The time from catheters placement to the administration of opioids

    24 hours postoperatively

Secondary Outcomes (6)

  • Pain intensity (NRS 0-10/10)

    24 hours postoperatively

  • Total morphine consumption.

    24 hours

  • Catheter displacement.

    24 hours

  • Patient satisfaction with application of the catheters.

    24 hours

  • The degree of morphine-related side effects (PONV, itching, fatigue, etc.).

    24 hours

  • +1 more secondary outcomes

Study Arms (2)

Intervention

ACTIVE COMPARATOR

Ropivacaine

Drug: Ropivacaine

Control

PLACEBO COMPARATOR

Isotonic saline

Drug: Saline

Interventions

2 x 30 ml ropivacaine 0,2% and an elastomere pump with 200 ml ropivacaine 0,2%, infusion rate 8 ml/hour

Intervention
SalineDRUG

2 x 30 mL isotonic saline and an elastomere pump with 200 ml isotonic saline, infusion rate 8 ml/hour

Control

Eligibility Criteria

Age18 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • + years of age.
  • Scheduled for elective Caesarean Section in spinal anaesthesia.
  • Have received thorough information, verbally and in written, and signed the "Informed Consent" form on participation in the trial.

You may not qualify if:

  • Inability to cooperate
  • Inability to understand Danish
  • Allergy to local anaesthetics or opioids
  • Excessive daily intake of opioids, according to the discretion of the investigator
  • Local infection at the site of injection or systemic infection
  • Difficult visualisation of muscular and fascial structures on ultrasound, necessary to correct blockade and catheter placement.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of anaesthesiology

Roskilde, 4000, Denmark

Location

Related Publications (1)

  • Steingrimsdottir GE, Hansen CK, Borglum J. Ultrasound-guided transmuscular quadratus lumborum catheters for elective caesarean section: A protocol for a single-centre, double-blind randomised trial. Acta Anaesthesiol Scand. 2020 Sep;64(8):1218-1223. doi: 10.1111/aas.13601. Epub 2020 Apr 22.

MeSH Terms

Conditions

Pain, Postoperative

Interventions

RopivacaineSodium Chloride

Condition Hierarchy (Ancestors)

Postoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesChloridesHydrochloric AcidChlorine CompoundsInorganic ChemicalsSodium Compounds

Study Officials

  • Jens Børglum, MD PhD

    Zealand University Hospital, University of Copenhagen

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 4, 2018

First Posted

September 10, 2018

Study Start

September 4, 2018

Primary Completion

April 8, 2020

Study Completion

April 8, 2020

Last Updated

March 3, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations